<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4477</td>
<td>Highlights of This Issue</td>
<td></td>
</tr>
<tr>
<td>4479</td>
<td>SPECIAL FEATURES</td>
<td></td>
</tr>
<tr>
<td>4479</td>
<td><strong>CCR Translations</strong></td>
<td><strong>Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer?</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adam S. Crystal and Alice T. Shaw <strong>See article p. 4682</strong></td>
</tr>
<tr>
<td>4482</td>
<td><strong>MicroRNA Dissects Out Dangerous Pancreatic Cysts from All the Rest</strong></td>
<td>Ryan M. Thomas and Jason B. Fleming <strong>See article p. 4713</strong></td>
</tr>
<tr>
<td>4485</td>
<td><strong>CCR New Strategies</strong></td>
<td><strong>New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marc Ladanyi, Marjorie G. Zauderer, Lee M. Krug, Tatsuo Ito, Robert McMillan, Matthew Bott, and Filippo Giancotti</td>
</tr>
<tr>
<td>4491</td>
<td><strong>CCR Perspectives in Drug Approval</strong></td>
<td><strong>The European Medicines Agency Review of Eribulin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Elias Pean, Sigrid Klaar, Eva Gil Berglund, Tomas Salmonson, Jeanett Borregaard, Kenneth F. Holland, Jens Ersboll, Eric Abadie, Rosa Giuliani, and Francesco Pignatti</td>
</tr>
<tr>
<td>4498</td>
<td><strong>Statistics in Clinical Cancer Research</strong></td>
<td><strong>Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Jack Lee, Nan Chen, and Guosheng Yin <strong>4560</strong></td>
</tr>
<tr>
<td>4508</td>
<td><strong>Molecular Pathways</strong></td>
<td><strong>Molecular Pathways: Targeting Hsp90—Who Benefits and Who Does Not</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maurizio Scaltriti, Shaheenah Dawood, and Javier Cortes <strong>4560</strong></td>
</tr>
<tr>
<td>4514</td>
<td><strong>Molecular Pathways: Targeting the TGF-β Pathway for Cancer Therapy</strong></td>
<td>Anna L. Smith, Tyler P. Robin, and Heide L. Ford <strong>4560</strong></td>
</tr>
<tr>
<td>4522</td>
<td><strong>Perspective</strong></td>
<td><strong>Optimizing Cancer Treatments to Induce an Acute Immune Response: Radiation Abscopal Effects, PAMPs, and DAMPs</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Charles M. Ludgate <strong>4560</strong></td>
</tr>
<tr>
<td>4526</td>
<td><strong>Reviews</strong></td>
<td><strong>Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lawson Eng, Abul Kalam Azad, Steven Habbous, Vincent Pang, Wei Xu, Anke H. Maitland-van der Zee, Sevtap Savas, Helen J. Mackay, Eitan Amir, and Geoffrey Liu <strong>4560</strong></td>
</tr>
<tr>
<td>4538</td>
<td><strong>Promising Personalized Therapeutic Options for Diffuse Large B-cell Lymphoma Subtypes with Oncogene Addictions</strong></td>
<td>James J. Steinhardt and Ronald B. Gartenhaus <strong>4560</strong></td>
</tr>
<tr>
<td>4549</td>
<td><strong>HUMAN CANCER BIOLOGY</strong></td>
<td><strong>Survival Signals and Targets for Therapy in Breast Implant–Associated ALK~Anaplastic Large Cell Lymphoma</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Melissa G. Lechner, Carolina Megiel, Connor H. Church, Trevor E. Angell, Sarah M. Russell, Bikki B. Sevell, Julie K. Jang, Garry S. Brody, and Alan L. Epstein <strong>4560</strong></td>
</tr>
<tr>
<td>4560</td>
<td></td>
<td><strong>Chromosome 5q Loss in Colorectal Flat Adenomas</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quirinus J.M. Voorham, Beatrix Carvalho, Angela J. Spiertz, Nicole C.T. van Grieken, Sandra Mongera, Eveline J.A. Rondag, Mark A. van de Wiel, Ekaterina S. Jordanova, Bauke Ylstra, Martin Kliment, Heike Grabsch, Bjorn J. Rembacken, Tomio Arai, Adriaan P. de Bruine, Silvia Sanduleanu, Philip Quirke, Chris J.J. Mulder, Manon van Engeland, and Gerrit A. Meijer <strong>4560</strong></td>
</tr>
</tbody>
</table>
Identification and Targeting \textit{ROS1} Gene Fusions in Non–Small Cell Lung Cancer
Kurtis D. Davies, Anh T. Le, Mariana F. Theodoro, Margaret C. Skokan, Dara L. Aisner, Eamon M. Berge, Luigi M. Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli, Marco Alloisio, Armando Santoro, D. Ross Camidge, Marileila Varella-Garcia, and Robert C. Doebele

Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation
Zhenfeng Duan, Jianming Zhang, Edwin Choy, David Harmon, Xianzhe Liu, Petur Nielsen, Henry Mankin, Nathanael S. Gray, and Francis J. Hornicek

The Pivotal Role of Integrin β1 in Metastasis of Head and Neck Squamous Cell Carcinoma
Dongsheng Wang, Susan M. Müller, A.R.M. Ruhul Amin, Donghai Huang, Ling Su, Zhongliang Hu, Mohammad Aminur Rahman, Sreenivas Nannapaneni, Lydia Koenig, Zhengjia Chen, Mourad Tighiouart, Dong M. Shin, and Zhuo G. Chen

Dual Targeting of mTOR and Aurora-A Kinase for the Treatment of Uterine Leiomyosarcoma
Kari J. Brewer Savannah, Elizabeth G. Demicco, Kristelle Lusby, Markus PH. Ghalbim, Roman Belousov, Eric Young, Yiqun Zhang, Kai-Lieh Huang, Alexander J. Lazar, Kelly K. Hunt, Raphaël E. Pollock, Chad J. Creighton, Matthew L. Anderson, and Dina Lev

Role of Hedgehog Signaling in Malignant Pleural Mesothelioma
Yandong Shi, Ubiratan Moura, Isabelle Opitz, Alex Soltermann, Hubert Rehrauer, Svenja Thies, Walter Weder, Rolf A. Stahel, and Emanuela Felley-Bosco

An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas
Katherine A. Murphy, Melissa G. Lechner, Flavia E. Popescu, Jessica Bedi, Stacy A. Decker, Peisheng Hu, Jami R. Erickson, M. Gerard O’Sullivan, Lauryn Swier, Andres M. Salazar, John R. Ohlfest

Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Claire Fabre, Naoya Mimura, Kathryn Bobb, Sun-Young Kong, Gülü Gorgun, Paul G. Richardson, Teru Hideshima, and Kenneth C. Anderson

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Johannes M. Heuckmann, Hyatt Balke-Want, Florentine Larousserie, Martin Peifer, Martin L. Soe, Mirjam Koker, Lydia Meder, Christine M. Lovly, Lukas C. Heukamp, William Pao, Ralf Kipppers, and Roman K. Thomas

See commentary p. 4479

Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Claire Fabre, Naoya Mimura, Kathryn Bobb, Sun-Young Kong, Gülü Gorgun, Paul G. Richardson, Teru Hideshima, and Kenneth C. Anderson

HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy
Kuen-Tyng Lin, Yi-Wei Wang, Chiu-Tong Chen, Chun-Ming Ho, Wen-Hui Su, and Yuh-Shan Jou

Clinical Cancer Research
Epstein-Barr Virus Infection and Expression of B-cell Oncogenic Markers in HIV-Related Diffuse Large B-cell Lymphoma
Chun Chao, Michael J. Silverberg, Otoniel Martinez-Maza, Margaret Chi, Donald I. Abrams, Reina Haque, Hongbin D. Zha, Michelle McGuire, Lanfang Xu, and Jonathan Said

miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts
Hanno Matthaei, Dennis Wylie, Maura B. Lloyd, Marco Dal Molin, Jon Kemppainen, Skye C. Mayo, Christopher L. Wolfgang, Richard D. Schulick, Laura Langfield, Bernard F. Andress, Alex T. Adai, Ralph H. Hruban, Anna E. Szafranska-Schwarzbach, and Anirban Maitra

The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5' and 3' Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers
Rui Wang, Yunjian Pan, Chenguang Li, Haichuan Hu, Yang Zhang, Hang Li, Xiaoyang Luo, Jie Zhang, Zhaoyuan Fang, Yuan Li, Lei Shen, Hongbin Ji, David Garfield, Yihua Sun, and Haifuan Chen

A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy
Mingying Zhang, Sourindra Maiti, Chantale Bernatchez, Helen Huls, Brian Rabinovich, Richard E. Champlin, Luis M. Vence, Patrick Hwu, Laszlo Radvanyi, and Laurence J.N. Cooper

CpG Island Methylator Phenotype–Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis
Tao Fu, Emmanouil P. Pappou, Angela A. Guzzetta, Jana Jeschke, Ruby Kwak, Pujan Dave, Craig M. Hooker, Richard Morgan, Stephen B. Baylin, Christine A. Iacobuzio-Donahue, Christopher L. Wolfgang, and Nita Ahuja

Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
Yu Imamura, Teppei Morikawa, Xiaoyun Liao, Paul Lochhead, Aya Kuchiba, Mai Yamauchi, Zhi Rong Qian, Reiko Nishihara, Jeffrey A. Meyerhardt, Kevin M. Haigis, Charles S. Fuchs, and Shuji Ogino

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
Andres Cervantes, Elena Elez, Desamparados Roda, Jeffrey Ecsedy, Teresa Macarulla, Kathirk Venkatakrishnan, Susana Roselló, Jordi Andreu, JungAh Jung, Juan Manuel Sanchez-Garcia, Adelaida Piera, Inma Blasco, Laura Maños, José-Alejandro Pérez-Fidalgo, Howard Fingert, Jose Baselga, and Josep Tabernero

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
E. Claire Dees, Roger B. Cohen, Margaret von Mehren, Thomas E. Stinchcombe, Hua Liu, Kathirk Venkatakrishnan, Mark Manfredi, Howard Fingert, Howard A. Burris III, and Jeffrey R. Infante

Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

LETTER TO THE EDITOR
Biomarkers in Hepatocellular Carcinoma—Letter
Nicola Personeni, Lorenza Rimassa, and Armando Santoro

ABOUT THE COVER
Wright–Giemsa-stained cytopin of early passages of TLBR-2 cells in culture. This cell line derived from an aggressive breast implant–associated T-cell CD30⁺ALK⁺ anaplastic large cell lymphoma (ALCL) shows typical morphologic features, including enlarged nuclei with frequent mitotic figures, multiple prominent nucleoli, pale cytoplasm with vesiculation, and occasional multinucleated giant cells (original magnification, ×400). Along with TLBR-1 and -3, it represents a new model for breast implant–associated ALCL and is characterized by a near triploid karyotype, specific chemotherapy drug sensitivities, and high expression of several pathway signals including Notch1, survivin, antiapoptotic genes, IL-6 and IL-2 autocrine cytokines, and STAT3, which seem to be associated with the oncogenesis and growth for these unique cancers. For details, see the article by Lechner and colleagues on page 4549 of this issue.

Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid

Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders
Jooeun Bae, Robert Smith, John Daley, Naoya Mimura, Yu-Tzu Tai, Kenneth C. Anderson, and Nikhil C. Munshi

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma